An intensive program with quadruplet induction and consolidation plus tandem autologous stem cell transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients: a phase II study of the Intergroupe Francophone du Myélome (IFM 2018-04)

2023-509383-15-00 Therapeutic exploratory (Phase II) Ongoing, recruitment ended

Start 5 Jul 2024 · Status Ongoing, recruitment ended · 1 EU/EEA countries · 13 sites

Overview

Sponsor-declared trial summary

Phase Therapeutic exploratory (Phase II)
Status Ongoing, recruitment ended
Participants planned 50
Countries 1
Sites 13

Multiple Myeloma

Key facts

Sponsor
Centre Hospitalier Universitaire De Nantes
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Hemic and Lymphatic Diseases [C15]
Trial duration
5 Jul 2024 → ongoing
Decision date (initial)
2024-07-05
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2023-509383-15-00
EudraCT number
2018-001960-45

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Multiple Myeloma

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Centre Hospitalier Universitaire De Nantes

Sponsor organisation
Centre Hospitalier Universitaire De Nantes
Address
5 Allee De L Ile Gloriette, Cs 69301 Cs 69301
City
Nantes Cedex 1
Postcode
44093
Country
France

Scientific contact point

Organisation
Centre Hospitalier Universitaire De Nantes
Contact name
Philippe MOREAU

Public contact point

Organisation
Centre Hospitalier Universitaire De Nantes
Contact name
Philippe MOREAU

Locations

1 EU/EEA country · 13 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ongoing, recruitment ended 50 13
Rest of world 0

Investigational sites

France

13 sites · Ongoing, recruitment ended
Centre Hospitalier Universitaire De Poitiers
hematology, 2 Rue De La Miletrie, 86000, Poitiers
Centre Hospitalier Universitaire De Lille
hematology, Rue Michel Polonowski, 59000, Lille
Centre Hospitalier Universitaire De Bordeaux
hematology, Avenue De Magellan, 33600, Pessac
Centre Hospitalier Universitaire De Rennes
hematology, 2 Rue Henri Le Guilloux, 35000, Rennes
Centre Hospitalier Universitaire Grenoble Alpes
hematology, Boulevard De La Chantourne, Cs 10217, Grenoble Cedex 9
Hospices Civils De Lyon
hematology, 165 Chemin Du Grand Revoyet, 69310, Pierre Benite
Institut Universitaire Du Cancer Toulouse-Oncopole
hematology, 1 Avenue Irene Joliot Curie, 31059, Toulouse Cedex 9
Centre Hospitalier Universitaire De Caen Normandie
hematology, Avenue De La Cote De Nacre, Cs 30001, Caen Cedex 9
Centre Hospitalier Departemental Vendee
hematology, Boulevard Stephane Moreau, 85925, La Roche Sur Yon Cedex 9
Centre Hospitalier Regional Universitaire De Tours
hematology, 2 Boulevard Tonnelle, 37000, Tours
Centre Hospitalier Universitaire De Dijon
hematology, 14 Rue Paul Gaffarel, 21000, Dijon
Centre Hospitalier Universitaire De Nantes
hematology, 5 Allee De L Ile Gloriette, Cs 69301, Nantes Cedex 1
CHRU De Nancy
hematology, 11 Rue Du Morvan, Bp 80001, Vandoeuvre Les Nancy Cedex

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2024-07-05 2024-07-05 2024-07-05

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-06-05 France Acceptable
2024-07-02
2024-07-05